Ceolin C., Alessi A., Citron A., et al., “Sex Differences in Muscle–Respiratory Function Relationship in Lung Transplant Patients: A Longitudinal Study,” Journal of Cachexia, Sarcopenia and Muscle17, no. 2 (2026): e70244, 10.1002/jcsm.70244.
In the originally published version of the article, a number of p‐values in Table 1 were reported incorrectly. Specifically, the p‐value for BMI was given as 0.200 but should read < 0.001; for time since transplant, < 0.001 should read 0.890; for total medications taken, 0.007 should read 0.614; for duration of corticosteroid therapy, < 0.001 should read 0.061; and for CIRS‐CI, < 0.001 should read 0.770.
Incorrect Table 1:
| Variable | Total (n = 155) | Women (n = 67) | Men (n = 88) | p |
|---|---|---|---|---|
| Age (years), mean ± SD | 48.7 ± 13.3 | 44.6 ± 14.3 | 51.9 ± 11.5 | < 0.001 |
| BMI (kg/m2), mean ± SD | 22.9 ± 4.03 | 21.36 ± 3.46 | 24.2 ± 3.99 | 0.200 |
| ADL, mean ± SD | 5.84 ± 0.62 | 5.88 ± 0.48 | 5.81 ± 0.71 | 0.46 |
| Primary condition, n (%) | 0.01 | |||
| Cystic fibrosis | 46 (30.1%) | 28 (42.4%) | 18 (20.7%) | |
| Restrictive lung diseases | 34 (22.2%) | 16 (24.2%) | 18 (20.7%) | |
| Obstructive lung diseases | 24 (15.7%) | 5 (7.6%) | 19 (21.8%) | |
| Miscellaneous | 41 (26.8%) | 13 (19.7%) | 28 (32.2%) | |
| Vascular diseases | 8 (5.2%) | 4 (4.6%) | 4 (6.1%) | |
| Time since transplant (months), mean ± SD | 40.01 ± 80.71 | 40.94 ± 52.76 | 39.31 ± 97.05 | < 0.001 |
| Total medications taken, mean ± SD | 15.05 ± 3.86 | 14.87 ± 3.88 | 15.18 ± 3.87 | 0.007 |
| Duration of corticosteroid therapy (months), mean ± SD | 30.19 ± 47.98 | 38.51 ± 61.60 | 23.84 ± 33.12 | < 0.001 |
| CIRS‐CI, mean ± SD | 4.05 ± 1.67 | 4.00 ± 1.52 | 4.08 ± 1.79 | < 0.001 |
| Pulmonary volumes, mean ± SD | ||||
| VC (% predicted) | 78.5 ± 20.27 | 82.0 ± 20.61 | 73.0 ± 19.49 | 0.094 |
| FVC (% predicted) | 75.94 ± 20.52 | 78.40 ± 20.13 | 73.97 ± 20.74 | 0.013 |
| FEV1 (% predicted) | 78.0 ± 21.64 | 78.0 ± 20.81 | 77.0 ± 22.26 | 0.084 |
| FEV1/FVC ratio (%) | 84.20 ± 9.04 | 85.15 ± 8.57 | 83.41 ± 9.40 | 0.30 |
| TLC (% predicted) | 78.50 ± 17.07 | 83.0 ± 15.48 | 71.0 ± 17.00 | 0.200 |
| Muscle variables | ||||
| Hand grip strength (kg), mean ± SD | 26.49 ± 9.57 | 20.73 ± 5.90 | 30.86 ± 9.52 | 0.016 |
| ASMMI (kg/m2), mean ± SD | 6.51 ± 1.22 | 5.71 ± 0.97 | 7.12 ± 1.02 | < 0.001 |
| Low muscle strength, n (%) | 44 (28.8%) | 13 (8.4%) | 31 (20.1) | 0.03 |
| Low muscle mass, n (%) | 68 (44.4%) | 25 (16.2%) | 43 (27.9%) | 0.16 |
| Sarcopenia prevalence, n (%) | 29 (19.1%) | 10 (15.2%) | 19 (22.1%) | 0.06 |
Corrected Table 1:
| Variable | Total (n = 155) | Women (n = 67) | Men (n = 88) | p |
|---|---|---|---|---|
| Age (years), mean ± SD | 48.7 ± 13.3 | 44.6 ± 14.3 | 51.9 ± 11.5 | < 0.001 |
| BMI (kg/m2), mean ± SD | 22.9 ± 4.03 | 21.36 ± 3.46 | 24.2 ± 3.99 | < 0.001 |
| ADL, mean ± SD | 5.84 ± 0.62 | 5.88 ± 0.48 | 5.81 ± 0.71 | 0.46 |
| Primary condition, n (%) | 0.01 | |||
| Cystic fibrosis | 46 (30.1%) | 28 (42.4%) | 18 (20.7%) | |
| Restrictive lung diseases | 34 (22.2%) | 16 (24.2%) | 18 (20.7%) | |
| Obstructive lung diseases | 24 (15.7%) | 5 (7.6%) | 19 (21.8%) | |
| Miscellaneous | 41 (26.8%) | 13 (19.7%) | 28 (32.2%) | |
| Vascular diseases | 8 (5.2%) | 4 (4.6%) | 4 (6.1%) | |
| Time since transplant (months), mean ± SD | 40.01 ± 80.71 | 40.94 ± 52.76 | 39.31 ± 97.05 | 0.890 |
| Total medications taken, mean ± SD | 15.05 ± 3.86 | 14.87 ± 3.88 | 15.18 ± 3.87 | 0.614 |
| Duration of corticosteroid therapy (months), mean ± SD | 30.19 ± 47.98 | 38.51 ± 61.60 | 23.84 ± 33.12 | 0.061 |
| CIRS‐CI, mean ± SD | 4.05 ± 1.67 | 4.00 ± 1.52 | 4.08 ± 1.79 | 0.770 |
| Pulmonary volumes, mean ± SD | ||||
| VC (% predicted) | 78.5 ± 20.27 | 82.0 ± 20.61 | 73.0 ± 19.49 | 0.094 |
| FVC (% predicted) | 75.94 ± 20.52 | 78.40 ± 20.13 | 73.97 ± 20.74 | 0.013 |
| FEV1 (% predicted) | 78.0 ± 21.64 | 78.0 ± 20.81 | 77.0 ± 22.26 | 0.084 |
| FEV1/FVC ratio (%) | 84.20 ± 9.04 | 85.15 ± 8.57 | 83.41 ± 9.40 | 0.30 |
| TLC (% predicted) | 78.50 ± 17.07 | 83.0 ± 15.48 | 71.0 ± 17.00 | 0.200 |
| Muscle variables | ||||
| Hand grip strength (kg), mean ± SD | 26.49 ± 9.57 | 20.73 ± 5.90 | 30.86 ± 9.52 | 0.016 |
| ASMMI (kg/m2), mean ± SD | 6.51 ± 1.22 | 5.71 ± 0.97 | 7.12 ± 1.02 | < 0.001 |
| Low muscle strength, n (%) | 44 (28.8%) | 13 (8.4%) | 31 (20.1) | 0.03 |
| Low muscle mass, n (%) | 68 (44.4%) | 25 (16.2%) | 43 (27.9%) | 0.16 |
| Sarcopenia prevalence, n (%) | 29 (19.1%) | 10 (15.2%) | 19 (22.1%) | 0.06 |
In Table 2, the femoral neck BMD value for the total sample was also incorrect: 0.92 ± 0.49 should read 0.66 ± 0.15.
Incorrect Table 2:
| Variable | Total (n = 155) | Women (n = 67) | Men (n = 88) | p |
|---|---|---|---|---|
| Pretransplant evaluation, n (%) | ||||
| Vitamin D/calcium supplementation | 102 (62.5%) | 48 (72.7%) | 54 (61.4%) | 0.09 |
| Antiresorptive therapy | 29 (18.7%) | 9 (13.4%) | 20 (22.7%) | 0.10 |
| Anabolic therapy | 2 (1.3%) | 0 | 2 (2.3%) | 0.45 |
| Osteoporosis diagnosis | 34 (21.9%) | 13 (19.4%) | 21 (23.9%) | 0.01 |
| Posttransplant evaluation | ||||
| Densitometric values, mean ± SD | ||||
| T‐score lumbar | −1.71 ± 1.41 | −1.73 ± 1.36 | −1.69 ± 1.46 | 0.86 |
| T‐score femur neck | −1.92 ± 1.09 | −2.22 ± 0.94 | −1.70 ± 1.14 | < 0.001 |
| T‐score total hip | −1.53 ± 1.01 | −1.91 ± 0.94 | −1.25 ± 0.98 | < 0.001 |
| BMD lumbar | 0.92 ± 0.49 | 0.94 ± 0.73 | 0.90 ± 0.16 | 0.58 |
| BMD femur neck | 0.92 ± 0.49 | 0.62 ± 0.13 | 0.69 ± 0.15 | < 0.001 |
| BMD total hip | 0.77 ± 0.18 | 0.71 ± 0.14 | 0.83 ± 0.17 | < 0.001 |
| Diagnosis, n (%) | 0.10 | |||
| Osteopenia | 29 (18.7%) | 9 (13.4%) | 20 (22.7%) | |
| Osteoporosis | 82 (52.9%) | 25 (37.3%) | 57 (64.7%) | |
| At least one vertebral fracture, n (%) | 52 (33.5%) | 14 (20.9%) | 38 (43.2%) | 0.005 |
| Anti‐resorptive therapy, n (%) | 109 (70.3%) | 41 (61.2%) | 68 (77.3%) | 0.003 |
| Anabolic therapy, n (%) | 11 (7.1%) | 2 (3.0%) | 9 (10.2%) | 0.003 |
Corrected Table 2:
| Variable | Total (n = 155) | Women (n = 67) | Men (n = 88) | p |
|---|---|---|---|---|
| Pretransplant evaluation, n (%) | ||||
| Vitamin D/calcium supplementation | 102 (62.5%) | 48 (72.7%) | 54 (61.4%) | 0.09 |
| Anti‐resorptive therapy | 29 (18.7%) | 9 (13.4%) | 20 (22.7%) | 0.10 |
| Anabolic therapy | 2 (1.3%) | 0 | 2 (2.3%) | 0.45 |
| Osteoporosis diagnosis | 34 (21.9%) | 13 (19.4%) | 21 (23.9%) | 0.01 |
| Posttransplant evaluation | ||||
| Densitometric values, mean ± SD | ||||
| T‐score lumbar | −1.71 ± 1.41 | −1.73 ± 1.36 | −1.69 ± 1.46 | 0.86 |
| T‐score femur neck | −1.92 ± 1.09 | −2.22 ± 0.94 | −1.70 ± 1.14 | < 0.001 |
| T‐score total hip | −1.53 ± 1.01 | −1.91 ± 0.94 | −1.25 ± 0.98 | < 0.001 |
| BMD lumbar | 0.92 ± 0.49 | 0.94 ± 0.73 | 0.90 ± 0.16 | 0.58 |
| BMD femur neck | 0.66 ± 0.15 | 0.62 ± 0.13 | 0.69 ± 0.15 | < 0.001 |
| BMD total hip | 0.77 ± 0.18 | 0.71 ± 0.14 | 0.83 ± 0.17 | < 0.001 |
| Diagnosis, n (%) | 0.10 | |||
| Osteopenia | 29 (18.7%) | 9 (13.4%) | 20 (22.7%) | |
| Osteoporosis | 82 (52.9%) | 25 (37.3%) | 57 (64.7%) | |
| At least one vertebral fracture, n (%) | 52 (33.5%) | 14 (20.9%) | 38 (43.2%) | 0.005 |
| Anti‐resorptive therapy, n (%) | 109 (70.3%) | 41 (61.2%) | 68 (77.3%) | 0.003 |
| Anabolic therapy, n (%) | 11 (7.1%) | 2 (3.0%) | 9 (10.2%) | 0.003 |
These corrections do not affect the results or the overall conclusions of the study.
We apologize for this error.